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ABSTRACT 
Ryan Bash:  Development and Characterization of a Focally Induced Mouse Model 
of Glioblastoma Multiforme 
(Under the Direction of Terry A. Van Dyke) 
 
Glioblastoma multiforme (GBM) is a devastating tumor of the central nervous 
system and is the most frequently occurring primary brain tumor in adults.  While 
much progress has been made in reducing the mortality associated with other forms 
of cancer, morbidity from GBM remains unchanged.  The lack of progress in 
treatment of GBM highlights the continuing need for accurate preclinical animal 
models as a means of understanding pathogenesis and providing a resource for 
testing of potential therapies.   
To model the development of GBM, we have developed a system using 
genetically engineered mouse (GEM) models in which silent mutant alleles can be 
converted to active oncogenes or inactive tumor supressors using the cre-lox 
recombination system.  Through stereotactic injection of replication incompetent 
lentivirus expressing Cre-recombinase into the cortex of these animals, we have 
assessed the impact of known effectors of astrocytoma to induce and advance 
tumors originating from terminally differentiated astrocytes in the context of 
surrounding normal brain tissue.   
 
 iii 
Table of Contents 
Page 
 
List of Figures ....................................................................................................................v 
List of Tables .................................................................................................................... vi 
List of Abbreviations ...................................................................................................... vii 
List of Symbols..................................................................................................... ix 
 
Chapter 
I.  Introduction ....................................................................................................... 1 
          Features and grading of Glioma .................................................................. 1 
          Genetics of Gliomas .................................................................................... 3 
                    pRB ................................................................................................... 4 
                    PTEN ................................................................................................ 6 
                    Ras.................................................................................................... 8 
          Glioma Mouse Models ................................................................................ 9 
                    Retroviral RCAS/tva Models ............................................................. 9 
                    Transgenic Ras-driven Models ....................................................... 11 
                    RTK Signaling Aberrations .............................................................. 13 
                    Rb Inactivation ................................................................................ 14 
           
 iv
          Rationale for Engineering an Improved Mouse 
          Model of GBM ........................................................................................... 17 
 
II.  Somatic Induction of Focal GBM .................................................................... 23 
          Abstract ..................................................................................................... 23 
          Introduction ............................................................................................... 24 
          Results ...................................................................................................... 26 
          Discussion ................................................................................................. 32 
          Materials and Methods .............................................................................. 35 
 
References ......................................................................................................... 53
 v
List of Figures 
Figure               Page 
 
1.1  RB regulation of the cell cycle ...................................................................... 19 
1.2  Relevant PTEN/PI3K signaling .................................................................... 20 
1.3  GZT121 Transgene Design ........................................................................... 21 
2.1  Relevant genetic constructs ......................................................................... 40 
2.2  PTK-627 lentivirus structure ......................................................................... 42 
2.3  T121 Expression is Restricted to Astrocytes ..................................................... 43 
2.4  Stable Long Term T121 Expression .................................................................. 44 
2.5  RB loss and PTEN Reduction Results in Focal Hyperplasia ................................ 45 
2.6  Features of TR GBM’s .................................................................................... 46 
2.7  Histological Characterization of TR GBM ........................................................ 47 
2.8  Proliferation and Apoptosis in TR animals ........................................................ 48 
2.9  Features of GBM observed in terminal stage TRP Animals ................................. 49 
2.10  Tumor incidence ........................................................................................ 50 
2.11  Tumor Free Survival .................................................................................. 51 
 
 
 
 
 
 
 
 vi
List of Tables 
Table               Page 
 
1.1  Summary of glioma mouse models .............................................................. 22 
2.1  Genotypic abbreviations used ...................................................................... 41 
2.2  Somatic induction of astrocytomas in conditional GEM ............................... 52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii
List of Abbreviations 
 
4-OHT   4-hydroxy-tamoxifen 
AA    anaplastic astrocytoma 
CC    corpus callosum 
CDK4    cyclin dependent kinase 4 
CNS     central nervous system 
EGF    epidermal growth factor  
EGFR    epidermal growth factor receptor 
GAP    RasGTPase activating protein 
GBM    glioblastoma, glioblastoma multiforme 
GEM    genetically engineered mouse 
GFAP    glial fibrillary acidic protein 
H&E    hematoxylin and eosin 
HGA    high grade astrocytoma 
IF    immunofluorescence 
IHC    immunohistochemistry 
IP    intraperitioneally  
LOH    loss of heterozygosity 
LSL    loxP-stop-LoxP cassette 
LV    lateral ventricle 
mTOR   mammalian target of rapamycin  
NSCLC   Non-Small Cell Lung Cancer  
 viii 
OB    olfactory bulb 
PCR    polymerase chain reaction 
PDGFR   platelet-derived growth factor receptor 
PNET    primitive neuroectodermal tumors 
PI3K    phosphatidylinositol 3’-kinase 
Pten    phosphatase and tensin homology on    
    chromosome ten 
 
Rb    retinoblastoma 
Rbf    retinoblastoma family members 
RMS    rostral migratory stream 
RT-PCR   reverse transcription- polymerase chain reaction 
RTKs    Receptor tyrosine kinases  
SIN    self-inactivating 
Stat    signal transducer and activator of transcription  
SV40    simian virus 40 
SVZ    sub ventricular zone 
SVZa    anterior sub ventricular zone 
T121    first 121 amino acids of SV40 large T antigen 
TGFα    transforming growth factor-α 
TUNEL terminal deoxynucleotidyltransferase mediated   
                                           dUTP-end labeling 
VEGF    vascular endothelial growth factor 
WHO world Health Organization 
 
Wt wild type 
 ix
um    micro meter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x
LIST OF SYMBOLS 
 
α    alpha 
β    beta 
∆    delta 
µ    micro 
ζ    zeta 
 
  
Chapter I 
Introduction 
 
FEATURES AND GRADING OF GLIOMA 
Gliomas are the most commonly occurring tumor arising from the central 
nervous system.  In adult mammals, glial cells retain the ability for limited 
proliferation after development is completed, although neurons do not outside of 
specific regions (1-4).  Gliomas are classified according to the cell type comprising 
the majority of the tumor and include astrocytomas, oligodendrogliomas and oligo-
astrocytomas.  Astrocytomas are diffuse gliomas that maintain the morphological 
and molecular characteristics of astrocytes and account for >60% of all primary brain 
tumors(5).  Because gliomas rarely metastasize outside the CNS, histological 
classification of the tumors within the brain is the primary determinant of malignancy.   
       Pilocytic astrocytoma, or grade I astrocytoma, is the most common brain 
tumor in children and young adults. It accounts for about 5.7% of all gliomas(5). This 
tumor is found in the cerebellum, optic nerve, chiasm and hypothalamus. Typical 
histological features of pilocytic astrocytoma are bipolar cells (having two extended 
processes on opposing poles) with Rosenthal fibers (elongated eosinophilic bundles) 
that are immuno-reactive to GFAP (glial fibrillary acidic protein) and loose multi-polar 
cells with microcysts and granular bodies (rounded eosinophilic structures within a 
cell) that stain poorly with GFAP.  GFAP is a component of the astrocytic 
intermediate filament that is used as a marker for mature astrocytes. In the normal 
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brain, astrocyte proliferation is minimal. Pilocytic astrocytoma is a slow-growing 
tumor with a low rate (<1%) of mitosis, and no necrosis. This type of tumor is well 
circumscribed, is usually not infiltrative and has no tendency to be malignant(6). 
Genetically, pilocytic astrocytoma is associated with neurofibromatosis type 1(NF1), 
especially optic pathway gliomas.  It is curable using surgery with or without 
radiation therapy, and 80% of patients survive more than 20 years after diagnosis.  
Low-grade astrocytomas, World Health Organization (WHO) grade II, are 
slow-growing tumors, accounting for ~40% of gliomas(5).  They are characterized by 
a high degree of cellular differentiation and diffuse infiltration of the surrounding 
tissue.  The mean survival can range from 6-8 years, with a high rate of curative 
treatment, depending on the extent of surgery, location, proliferative potential of the 
neoplasm, and the accumulation of multiple genetic alterations.   
Anaplastic astrocytoma, WHO grade III, is an intermediate grade tumor that 
appears to develop from low-grade astrocytomas and accounts for 7.5% of 
gliomas(5).  Localized hypercellularity produces a discernible mass within the 
surrounding brain tissue.  This focal hypercellularity exists in combination with 
atypical nuclei and less differentiated cells that are frequently not morphologically 
identifiable as astrocytes(6).  Typical treatment includes surgical resection when 
practical, followed by radiation therapy.  The mean survival from these tumors is 2-3 
years, with key prognostic factors being progression to GBM (decrease in survival) 
and the presence of an oligodendroglial component (increase in survival)(6;7).   
Glioblastoma multiforme (GBM), WHO Grade IV, is the most malignant and 
common manifestation of astrocytic tumors accounting for more than 50% of 
 3
cases(5).  Approximately 90% of GBM’s arise without evidence of a less severe 
precursor lesion, and typically affect older patients(8;9).  The other 10% develop 
from pre-existing diffuse or anaplastic astrocytomas, and typically arise in younger 
patients(8;9).  Despite having similar histological presentation and prognosis, 
primary and secondary GBM typically harbor differing genetic alterations.  Primary 
GBMs are characterized by a loss of heterozygosity 10q in 70% of cases, PTEN 
(phosphatase and tensin homologue) mutations (25%), EGFR (epithelial growth 
factor receptor) amplification (36%),and p16INK4a deletion (31%)(8-11).  In secondary 
GBM, TP53 mutations are the most frequently occurring alterations and are present 
in 60% of precursor lesions, followed by loss of heterozygosity 10q (70%) upon 
progression to GBM(8-11).  Progression to GBM from anaplastic astrocytoma is 
characterized histologically by regional necrosis, and/or microvascular proliferation 
in addition to an increased proliferative index(12).  Despite the presence of a central 
focus, infiltrative growth usually precludes complete surgical resection and makes 
eradicating tumor cells with chemotherapy or radiation therapy nearly impossible 
without extensive damage to surrounding brain parenchyma.  GBM is associated 
with an exceptionally poor prognosis and a mean survival time of 9-12 
months(6;12;13).  
Recent large scale efforts have been made to accurately and systematically 
identify molecular aberrations present in human GBM(14;15).  In particular, The 
Cancer Genome Atlas (TCGA) Research Network has reported an interim analysis 
of 206 GBM’s isolated from human patients identifying changes in DNA copy 
number, gene expression and methylation(15).  The most frequent alterations were 
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in RTK/Ras/PI(3)K signaling (88%), p53 signaling (87%) and RB signaling (78%).  A 
similar study was perfomed independently for 22 human GBMs and obtained similar 
results(14).   Both studies provide comprehensive analyses of molecular biological 
data leading to an improved understanding of the molecular causes of GBM. 
Despite years of active research including clinical trials for pathway-targeted 
therapies, effective management of astrocytomas and mortality rates from them 
have not changed significantly over since the advent of radiation therapy.  However, 
our understanding of the molecular and genetic alterations likely underlying these 
devastating tumors has greatly increased due to the analysis of human tumors and 
derivative cell lines and to the development of mouse models.  These models are 
vital tools that will be used to explore the development and progression of these 
diseases, as well as aid in testing potential targets for therapies in the clinic. 
 
GENETICS OF GLIOMA 
 
pRb 
 
 
 pRb and the paralogous proteins, p107 and p130 (collectively referred to as 
pRbf) play a critical role in regulating the E2F family of transcription factors.  During 
cellular quiescence and the G1 phase, hypophosphorylated Rb associates with 
specific E2F proteins (E2F1-3)(16). Together these complexes actively repress E2F-
dependent S phase gene transcription(17;18) through recruitment of histone 
deacetylases and other chromatin remodeling factors(19-21).  Cell cycle progression 
is initiated by mitogenic signals that stimulate cyclin D/CDK4, 6 and cyclin E/CDK2 
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complexes to phosphorylate Rb.  Hyperphosphorylation of Rb releases it from the 
E2F transcriptional complex that then directs transcriptional DNA-replication 
machinery and nucleotide biosynthesis, thereby facilitating cell cycle progression 
(Fig. 1.1). Cyclin-dependent kinase inhibitors, including the INK4 and p21 proteins, 
provide an additional layer of regulation by negatively regulating CDK function(22).  
While inherited Rb mutation in humans predisposes children to retinoblastoma and 
osteosarcoma(23), somatic loss of Rb function, or aberrations in other functions 
along the Rb pathway (Fig. 1.2), such as loss of p16INK4a or activation of 
CDK4/cyclinD, have been detected in the majority of human sporadic cancers(24-
27).  The observation that these mutations are mutually exclusive in a single tumor is 
genetic evidence for a linear tumor suppression pathway.  pRb pathway mutations 
have been detected in 68-78%(14;15) of human GBM’s. 
While genetic engineering strategies in the mouse provide tools to investigate 
the genetic requirements of tumor onset and progression(28), the analysis of cell-
specific somatic pRb inactivation is challenging.  Rb deficiency causes embryonic 
lethality in mice, while heterozygous and chimeric mice develop only a small subset 
of tumors including pituitary and thyroid tumors(29;30).  The limited tumor spectrum 
is believed to be the result of compensation by p107 and p130 in most cell types(30).  
Therefore, to analyze pRb pathway inactivation at the most downstream step by 
allele disruption would require 4-6 mutant alleles, one of which would be conditional, 
making further modeling of additional events prohibitive. Thus, a strategy was 
developed to dominantly interfere with pRb, p107 and p130 by cell specific 
expression of a truncated SV40 T-antigen, containing only the amino-terminal 121 
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amino acids and referred to as T121.   T121 binds to pRb, p107 and p130 and 
inactivates their ability to negatively regulate E2F’s(31-35).  Using a single 
transgenic allele expressing this dominant interfering protein the Van Dyke lab has 
thus far inactivated pRb function in several cell types in the mouse, predisposing 
them to tumorigenesis(36-39).  In each case, aberrant proliferation is induced and is 
accompanied by apoptosis, initiating the process of tumorigenesis. 
 
 PTEN/PI3K 
   
 The lipid Phosphatase and Tensin Homolog (PTEN) functions as a tumor 
suppressor and is inactivated in a wide variety of human malignant neoplasms 
including glioblastoma, breast, and prostate(40;41).  Loss of the chromosome region 
10q23.3 containing PTEN is known to occur frequently in GBM(15).  PTEN directly 
antagonizes the activity of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR 
pathway(40;42;43).  This is an evolutionarily conserved signaling cascade 
influencing multiple cellular functions including proliferation, growth, survival and 
migration(44).  Activation of PI3-kinase by growth factor or extracellular matrix 
(ECM)-dependent signaling leads to synthesis of phosphatidylinositol 3,4,5-
phosphate (PIP-3) that is dephosphorylated by PTEN to phosphatidylinositol (4,5)-
diphosphate (PIP-2)(45).  PIP-3 is responsible for recruiting AKT and 
phosphoinositide dependent kinase-1 (PDK1) to the plasma membrane by binding to 
their pleckstrin homology (PH) domains(44).   At the plasma membrane AKT is 
activated by phosphorylation of its activation loop by PDK1(46) and phosphorylation 
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of its hydrophobic motif by Mammalian Target of Rapamycin Complex 2 (mTORC2), 
which is rapamycin-insensitve(47).  Activated AKT is then capable of 
phosphorylating multiple proteins responsible for a variety of cellular processes.   
AKT phosphorylation of the forkhead (FOXO) family of transcription factors 
negatively regulates their activity by inducing their release from DNA, promoting cell 
survival and increasing proliferation by preventing activation of the proapoptotic 
genes Fas ligand (Fas-L), tumor necrosis factor-related apoptosis inducing ligand 
(TRAIL) and Bcl-2 interacting mediator of cell death (Bim)(48-50). Activated Akt also 
downregulates p27 levels and inactivates Gsk-3, resulting in stabilization of cyclin 
D1, thus leading to increased cellular proliferation(51).  Phosphorylation of the 
tuberosclerosis complex TSC1/TSC2 by AKT inhibits its ability to negatively regulate 
Ras homolog enriched in brain (RHEB), activating the rapamycin-sensitive mTOR 
complex (mTORC1)(52).  The kinase activity of mTOR in the mTORC1 complex 
regulates protein synthesis and ribosome biogenesis via eukaryotic translation 
initiation factor 4E (4EBP1) and ribosomal S6 kinase(53). 
 PTEN has also been shown to have a role in cell mobility in vivo and in vitro.  It 
downregulates cell spreading and focal adhesion in fibroblast and glioma cell 
lines(54). Human glioma cell lines lacking PTEN have been found to be highly 
invasive.  Restoration of PTEN in these lines greatly reduces their capacity for 
invasion(55;56).  It has also been shown that a CNS-specific knockout of PTEN 
disrupts the organized structure of cerebellum presumably as a result of aberrant 
migration(57).  While loss of PTEN is clearly plays an important part in glioma 
progression, its multiple roles remain to be completely explored. 
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 Ras 
  
 Although K-Ras mutation is rare in human brain tumors, it does appear to be 
frequently activated by RTKs(15;58).  Many labs have demonstrated a role for K-Ras 
or H-ras in high-grade astrocytomas.  Transgenic mice harboring a GFAP-regulated 
Ha-RasV12 allele developed astrocytoma at severities dependent upon transgene 
expression level(59).  However in another study(60) K-rasG12D (a constitutively active 
point mutant) was not sufficient to induce glioma.  These conflicting results may be 
attributable to functional and regional differences in K-ras and H-ras expression, or a 
difference in potency of the 2 Rases.  It is also potentially attributable to 
methodological differences between the two studies, H-ras being expressed broadly 
throughout the brain and K-ras being delivered strictly to a small portion of the cortex. 
The NF1 tumor suppressor gene is a negative regulator of Ras activity, 
converting it from a GTP-bound to a GDP-bound state.  Astrocyte-specific 
inactivation of Nf1 using crosses to specific Cre strains is not sufficient to predispose 
mice to astrocytoma(61).  However it has recently been found that NF1 is deleted or 
harbors inactivating mutations in 23% of GBM samples(15), emphasizing the 
importance of the negative Ras regulation.   
 K-ras is a downstream effector of several receptor tyrosine kinases, including 
EGFR and PDGFRα which are frequently activated by mutation and/or amplification 
in human high grade astrocytomas.  Although gain-of-function mutations in EGFR 
occur frequently in high-grade gliomas (~40% of GBM cases)(62), transgenic and 
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somatic delivery approaches to overexpress wildtype and mutant forms of EGFR in 
astrocytes have not generated astrocytoma, but do increase the number of glial 
cells(59;63).  Because EGFR mutations are observed mainly in high grade gliomas, 
being mutated or amplified in 45% of GBM’s(15) and largely absent in low-grade 
disease, it is thought that it is important for disease progression rather than initiation.  
The relevant downstream effector pathways in disease etiology are largely unknown.  
However KRas can regulate several pathways including MAPK, PKC, JNK and PI3K. 
 
 
MOUSE MODELS OF GLIOMA 
Retroviral RCAS/tv-a Models 
 
Delivery of retrovirus carrying oncogenes has become a useful technique in 
altering the somatic genetics of postnatal mice(64;65).  The use of recombinant 
retrovirus is effective and often more convenient than generating transgenic mice.  
The avian retrovirus (RCAS) cannot infect normal murine cells because these cells 
do not express the cognate receptors for the virus.  Holland, Varmus and colleagues 
established transgenic mouse lines that express avian retroviral receptors under the 
control of a GFAP (Gtv-a) or nestin promoter (Ntv-a)(65).  Nestin is an intermediate 
filament protein expressed broadly in the developing CNS, and restricted in the adult 
to a limited neural precursor population.  Neonatal transgenic brains were then 
infected with recombinant avian retrovirus carrying the gene of interest.  Using 
neonates is important as the CNS cells are still proliferating and are capable of being 
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infected.  Akt and constitutively active K-RasG12D together, but not either alone, were 
capable of inducing glioma with high frequency(66).  PDGFβ itself was sufficient to 
induce GBM formation, which was accelerated in an INK4a-Arf deficient 
background(64). On the other hand, several common genetic alterations failed to 
induce glioma.  For example, even on INK4a-Arf or p53 deficient backgrounds, 
overexpressing EGFR induced less severe glioma-like lesions than overexpressing 
PDGF, Akt and Ras(63;64;66) .  Interestingly, p53 deficiency did not cooperate with 
PDGFβ to accelerate glioma formation(64).  This approach also shed light on the 
possible origin of the tumor cells.  Gene transfer into mice that express the receptor 
targeted to neural progenitor cells (Ntv-a) caused more aggressive gliomas and with 
a higher frequency than mice expressing the receptor targeted to differentiated glial 
cells (Gtv-a)(64).  For example, the combination of Akt and activated K-Ras allele 
only induced GBM in Ntv-a, but not Gtv-a mice(66).   These results indicate that 
neural progenitor cells may be more predisposed than differentiated astrocytes to 
tumorigenesis upon oncogenic stimuli.  However, because recombinant RCAS virus 
can only integrate into proliferating cells, the high proliferation rate of the progenitors 
(as in Ntv-a mice) could also be influencing the tumor phenotype.  Another potential 
use of this approach is to evaluate the differentiation status of tumor cells during 
tumor progression.  When PDGF or polyoma virus middle T antigen was delivered, 
mice developed mixed oligodendrocytoma and astrocytic glioma at varying 
frequencies(64;66).  These results indicated that certain genetic alterations either 
have distinct roles in dedifferentiation of tumor cells or have a more profound impact 
on distinct glial lineages in this case. 
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Transgenic Ras-driven Models 
 
Using a mouse ES cell transgenic approach, mice harboring Ha-rasV12 under 
the control of the GFAP promoter developed glioma(59).  The phenotype is 
dependent on the transgene expression level. A high expressing line of mice 
develops GBM at two weeks, and is therefore not germline transmittable, while the 
low expression line develops low to high grade glioma (Grade II at 80%, Grade III at 
20%).  A variety of genetic mutations that frequently occur in human gliomas, such 
as Rb pathway and PTEN mutations, have also been found in tumors developing in 
this model.  However, whether these mutations correlate with tumor progression and 
at what frequency was not reported(59).   
The Ha-ras V12 study provided an interesting contrast to the previous study, in 
which somatic delivery of K-RasG12D itself was not sufficient to induce glioma(63).  
The contrasting results may be due to functional and regional differences of H-Ras 
and K-Ras expression.  K-RasG12D was delivered to the cortex of neonatal mice 
while Ha-rasV12 was expressed in much broader regions.  Alternatively, this 
discrepancy may also reflect differences in the methodology.  Since somatic delivery 
of K-RasG12D  only infected a small number of cells, Dai and Holland proposed that 
the likelihood of developing secondary events that accelerate tumorigenesis is 
low(64).  In contrast, numerous genetic alterations were found in the Ha-rasV12 
transgenic mice(59).  Thus, the RCAS delivery system may not identify the genetic 
alterations occurring during selective evolution subsequent to initiating events(64).   
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Further improvement in the somatic delivery approach will allow us to investigate the 
number of tumor cells necessary to develop secondary mutations vital for tumor 
progression and to observe the competition between tumor cells that develop 
different secondary mutations.   
 The NF1 tumor suppressor gene is a negative regulator of Ras activity (GAP), 
converting it from a GTP-bound to a GDP-bound protein(67).  It is located on the 
same chromosome as the p53 gene (human:17, Mouse:11) separated by 7 cM.   
This configuration makes it difficult to combine the nullizygosities of the two by 
conventional genetic crosses in mouse. Hence, Jacks, Parada and colleagues 
selected the rare  “cis” heterozygous null offspring from a cross between p53 and 
Nf1 null mice(68).   The “cis” mice develop low to intermediate grades of glioma with 
varying frequency depending on the background strains.  In a separate study, 
Parada and colleagues demonstrated that inactivating both alleles of NF1 (p53 intact) 
in astrocytes is not sufficient to induce glioma(61).  Since p53 null mice do not 
develop glioma, these studies clearly demonstrate that collaboration between the 
two is critical for glioma initiation.  The background dependence of the phenotype 
indicates the existence of modifier loci, which should also be of great interest. 
Considering the high incidence of Ras gain-of-function mutations in other 
types of solid human tumors(69), it is surprising that Ras mutations have rarely been 
found in human gliomas. Yet many transgenic mouse models overexpressing Ras 
develop glioma.  These discrepancies between human gliomas and mouse studies 
are not well understood. 
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RTK Signaling Aberrations 
 
Although gain-of-function mutations of EGFR occur frequently in high-grade 
human gliomas (~40% in GBM)(62;70;71), transgenic and somatic delivery 
approaches to overexpress WT and mutant forms of EGFR in the mouse have not 
generated severe tumor development as expected, but only increased the number of 
glial cells (gliosis)(63;72) .  EGFR knockout mice have a reduced number of GFAP 
expressing astrocytes and exhibit neuron degeneration(73-75).  Still, these knockout 
results need to be interpreted carefully since trophic support from other cell types 
during CNS development is well known. Given the success in generating gliomas 
with other RTK/Ras perturbations (PDGFR, H-Ras and K-Ras) these data are 
intriguing.   One explanation for the lack of tumorigenesis in this model is that EGFR 
mutations may only collaborate with other genetic mutations to accelerate 
tumorigenesis.  Consistent with this hypothesis, somatic delivery of EGFR to the 
INK4a-ARF deficient mice background increased the frequency of glioma-like 
legions compared to the WT or p53 deficient mice(63).   However, other mutations 
may be necessary to generate more malignant gliomas together with EGFR 
mutations. Another possibility is that the timing of EGFR mutations may be critical.  
Since EGFR mutations usually occur in high-grade human gliomas, preceding 
mutations may be needed to “prime” the tumor cells to accommodate upregulation of 
EGFR functions.  Finally, EGFR upregulation may require a different targeted 
population from the ones used in the above studies to exert its effects(76;77).  The 
EGF/EGFR signaling pathway has been proven vital for neural stem cell survival 
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(NSCs) in the CNS(76;77). Since EGFR signaling is important for CNS neural 
progenitor cell proliferation, these cells may be affected more by EGFR mutation 
than differentiated cells.  Supporting this hypothesis, TGF-α (EGFR related ligand) 
mutant mice, both hypomorphic and KO, have a reduced proliferation rate in the 
adult SVZ(78). 
 To examine the role of EGFR in the pathogenesis of oligodendroglioma, 
transgenic mice were generated expressing v-erbB, a transforming homologue of 
EGFR, under control of the S100β promoter(79).  S100β is expressed in 
oligodendroglia and astrocytes and is present in a wide variety of glial tumors.  The 
S100β-v-erbB mice developed low-grade oligodendroglioma but showed no signs of 
astrocytoma.  When crossed onto a heterozygous ink4a/arf or p53 background, the 
mice developed high-grade tumors, which maintained the characteristics of 
oligodendroglioma.  Comparative genomic hybridization in primary tumor samples as 
well as tumor cell lines revealed loss of distal portions of mouse chromosome 4, a 
region orthologous to human chromosome 1p, a region, which is commonly lost in 
human oligodendroglioma.   
 
  Rb Inactivation 
 
 The Rb pathway is the most frequently mutated pathway in human gliomas 
including GBM.  Transgenic models have been generated to inactivate pRb family 
members (pRb, p107, p130)(80) using cell specific promoters.  In the mouse, Rb 
family proteins have overlapping functions in suppressing tumorigenesis(81-83).  To 
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overcome this problem and eliminate the need for the generation of multiple 
knockout animals, a truncated SV40 T antigen, named T121, was used(84).   
Encoding the N-terminal portion of the large T antigen, T121, contains the sequence 
motif that binds to and inactivates all three Rb family members and triggers the J 
domain to disrupt the protein complex formed by Rbf and their associated proteins 
(Fig. 1.2)(85-87).   
 Prior work in the Van Dyke lab targeted T121 to astrocytes via the human glial 
fibrillary acidic protein (GFAP) regulatory region to test the hypothesis that 
astrocytes are the cell of origin for gliomas in human tumors.  GFAP is a marker for 
astrocytes in the adult brain.  A 2.2 kilobase 5’- flanking sequence derived from the 
human GFAP (hGFAP) gene was shown to direct astrocyte-specific transcription(88).  
Most mice generated with the GFAP promoter driving expression of T121 died 
perinatally due to severe glioma-like lesions of astrocytes and neural progenitor 
cells(36).  Notably the cellular population of the subventricular zone was expanded, 
coupled with diffuse hypercellularity throughout the brain.  Secondary structures 
including perivascular and perineuronal satellitosis were noted. 
 In an effort to bypass the perinatal lethality associated with the expression of 
the multi-copy T121 transgene under the control of the GFAP promoter, a conditional 
approach based on the Cre-LoxP system was used to reduce the transgene 
expression level(36).  After a single cross of the conditional transgenic (GZT121) to β-
actin-Cre mice, mice of this lineage (TgG(∆Z)T121) (Fig. 1.4) developed malignant 
anaplastic astrocytoma as adults with 100% penetrance.   However, high grade 
glioblastoma was not observed even after prolonged periods of time.   
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An effort was also made to determine the role of progenitor cells in 
astrocytoma formation using a similar approach.  In this case T121 expression was 
driven by the nestin promoter.  Nestin is an intermediate filament in the human 
central nervous system that has been characterized as a marker for neural 
progenitor cells that have the ability to give rise to multiple cell types(89;90).  
Expression of the intermediate filament is under strict temporal and spatial control in 
undifferentiated cells of the CNS.  Nestin expression has been observed in mice as 
early as embryonic day 7.75 and is down regulated as cells differentiate and migrate 
throughout the brain(91).  The subventricular zone (SVZ) of the brain is an area 
thought to be a source of neural stem cells (NSC) in adult brains.  No founder 
animals were generated using the nestin promoter to drive T121 expression, 
suggesting that an embryonic lethal phenotype was induced (Xiao and Van Dyke, 
unpublished).  It was hypothesized that the embryonic lethality was due to the high 
copy number of the transgene.  Again, a Cre-loxP conditional system was used to 
bypass perinatal lethality and reduce the transgene to a single copy.  T121 expression 
was restricted to neuroprogenitor cells beginning at embryonic day 11.5(92).
 
 
Transgenic embryos showed aberrant central nervous system (CNS) cell 
proliferation and apoptosis by embryonic day 13.5.  Defects in cortical development 
were evident at this time, including depletion of neural progenitors and aberrant 
cellular migration. Juvenile and adult brain morphologies were reproducibly 
abnormal. These aberrations resulted in highly penetrant behavioral phenotypes, 
including ataxia and seizures.  The data indicated that inactivation of pRbf in radial 
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glial cells, a population of neuroprogenitor cells, leads to specific disruptions in CNS 
cell patterning, but is not responsible for any type of CNS tumor. 
In mice, it appears that pRbf inactivation can only constitute an initiating event 
in the development of astrocytoma due to the long latency (>3 months) between pRb 
inactivation and the onset of life-threatening disease(36).  It is well established in 
human tumors that additional genetic events contribute to disease progression.  One 
such event that commonly occurs in the most malignant form of astrocytoma, GBM, 
is loss of PTEN.  Studies performed in the Van Dyke lab showed that PTEN 
heterozygosity accelerated astrocytoma development(36;93).  Because loss of 
PTEN is embryonic lethal(51), conditional alleles were generated in which loxP sites 
flank exons 4 and 5 (designated Ptenfl/fl), encoding a phosphatase domain critical for 
regulating the PI3K pathway.  Cre-mediated excision of exon 4 and exon 5 results in 
a PTEN null allele, producing an unstable transcript.  This system has been used to 
show that loss of PTEN results in increased cell survival and invasiveness (36;93).  
A summary of these models may be found in Table 1.1. 
 
RATIONALE FOR ENGINEERING IMPROVED MOUSE MODELS OF GBM 
 
While much progress has been made using the model systems described 
above, it is possible to improve on them by developing a model that features 
pertinent genetic alterations expressed at physiologically relevant levels in a small, 
localized population of mature astrocytes.  One major improvement of these models 
may come from the refinement of somatic delivery strategies.   Human tumors are 
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likely initiated from a single cell that acquires critical secondary alterations to gain a 
growth advantage.  A somatic delivery system limits the number of cells with induced 
events and is a closer mimic of the single cell of origin scenario.    Furthermore, this 
strategy is more convenient to study the impacts of multiple genetic alterations than 
the traditional approach, reducing the amount of breeding necessary in traditional 
GEM’s.  Finally, it can be used to study many important but unresolved issues in 
CNS tumor progression, especially in gliomagenesis, such as cell origins and 
regional predilection of tumor development, and tumor-microenviroment interaction.  
Recent improvements in viral vectors, particularly recombinant lentivirus, further 
enhance the efficiency of gene delivery.  In the current project, a stereotaxic injection 
of self-inactivating lentiviral vector is used to deliver Cre-recombinase into the 
cerebral cortex of existing GEM models, inactivating pRbf, activating Kras receptor 
tyrosine kinase, and inactivating the tumor suppressor PTEN, leading to GBM with 
short latency and high penetrance. 
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Figure1.1 RB regulation of the cell cycle.  Upper Panel.  Hyperphosphorylation of pRB 
family members by CDK’s induces appropriate entry into the S phase of the cell cycle 
through E2F activation.  The lower panel shows T121 binding to and inactivating pRb family 
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members allowing E2F transcription factors to drive S phase entry independently of normal 
signaling. 
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Figure 1.2.  Relevant PTEN/PI3K signaling.  Multiple downstream effectors of PI3K 
regulate diverse cell functions.  Many of these are important in controlling cell migration and 
invasion, protein synthesis, cell cycle entry and apoptosis. 
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Figure 1.3.  GZT121 Transgene Design.  In this configuration, T121 expression is controlled 
by a fragment of the human GFAP promoter and is abrogated until the LacZ cassette is 
deleted by Cre-mediated recombination.  Upon recombination in cells where the GFAP 
promoter is active, the T121 protein binds to and inactivates pRB family to promote 
inappropriate S phase entry. 
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Table 1.1  Summary of glioma mouse models 
 
Glioma models  CNS Tumors  Phenotype 
 
 
TgGFAP& 
Nestin–tva 
 
 
Astrocytoma 
including GBM 
1. Dependent on infection with RCAS 
containing mutant EGFR 
2. GBM induced by overexpression of 
PDGF, Middle T-antigen, and Akt with 
constitutively active K-RasG12D, but not by   
b-FGF and EGFR overexpression  
(Holland et al. 1998) 
 
 
TgGFAP-Ha-
Ras 
 
 
Astrocytoma 
including GBM 
 
1. Low-grade astrocytoma to GBM, multi-
focal and highly penetrant, severity 
depends on transgene expression level 
2. Secondary mutations found in Rb, p53 
and PTEN pathway (Ding et al. 2001) 
 
 
Cis NF1;p53 
null 
 
 
Grade II and III 
gliomas 
 
1.Grade II and III gliomas in cis 
heterozygotes.  
2.Severity and penetrance dependent on 
background strain (Cichowski and Jacks 
2001) 
 
 
TgGFAP--(∆Z)--
T121 
 
 
Grade III gliomas 
1. Grade III gliomas at 100% penetrance.  
2. Tumor progression accelerated on 
PTEN but not p53 deficient backgrounds 
(germline) 
3. PTEN deficiency (somatic) reduces 
apoptosis, enhances invasion and 
angiogenesis (Xiao et al. 2002) 
 
 
TgGFAP-Src 
 
 
Grade II and III 
gliomas 
1. Low and high grade gliomas developed 
in ~20% of transgenic mice  
2. Retarded growth, cerebellar ataxia and 
some hydrocephalus 
(Weissenberger et al. 1997) 
 
  
 
Chapter II 
Focal induction of GBM 
 
ABSTRACT 
  
Currently, there is no effective treatment for astrocytoma, including the most 
severe manifestation, glioblastoma multiforme (GBM).  In order to develop therapies 
targeted specifically to this disease, it is important to develop animal models which 
will be used to determine the molecular pathogenesis of the disease.  The Van Dyke 
Lab and others have developed genetically engineered mouse (GEM) models which 
target pathways frequently deregulated in human astrocytomas.  Specifically, 
conditionally inactive/active alleles of RB, KRAS and PTEN were used.  These 
genetic alterations were induced in the adult mice by Cre recombinase, which was 
delivered into mature cortical astrocytes via stereotactic injection of a self-
inactivating (SIN) lentiviral vector.  Animals with focal RB inactivation alone 
developed minimal focused hyperplasia.  Mice with RB inactivation combined with 
constitutively active KRAS developed GBM (grade IV) with long latency.  The 
additional loss of PTEN produced tumors with histopathological features of GBM 
with a shorter latency.  These results support the role of RB in tumor initiation and 
the roles of PTEN and KRAS in tumor progression.  This model also provides a 
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highly-penetrant, inducible system in which to study multiple aspects of disease 
progression from a single focus. 
 
 
INTRODUCTION 
  
Astrocytomas are the most commonly occurring malignant primary brain 
tumors in humans.  At this time, there are no effective treatments available for these 
diseases(12) and therapeutic regimens are largely palliative in nature.  Overall 
survival for all grades of astrocytoma have not changed significantly in the past fifty 
years(12;70).  GBM is the most severe manifestation of astrocytoma, WHO Grade IV, 
and is characterized by the presence of increased mitotic activity, necrosis and 
vascular proliferation(12).  GBM appears to arise via two distinct genetic 
pathways(12;94).  The progression of grade II or III astrocytoma to GBM is referred 
to as secondary GBM and may occur over a period of months to decades.  
Secondary GBM often retains features of the lower grade precursor including TP53 
mutations, PDGFR-α overexpression and RB family alterations (pRB, p107 and 
p130) (12;94;95).  GBM may also develop without any prior clinical history of brain 
tumor in the patient and is referred to as primary GBM.  Clinical cases of primary 
GBM display aberrations in cell-cycle regulatory factors, including the RB family 
members (20-30%), PTEN deletion and high frequencies (30-70%) of EGFR 
overamplification.  KRAS is not frequently mutated but is hyperactivated in many 
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cases of high grade astrocytoma(96;97), most probably as the result of the activation 
of upstream receptor tyrosine kinases (RTK) such as EGFR and/or PDGFR-α(70).   
 Unfortunately, the complexity of the brain and it’s prominence in basic human 
function prevent the detailed dissection of the molecular pathogenesis, in particular 
the role of tumor microenvironment, of astrocytomas based on the analysis of 
human tumor samples alone.  Relevant animal models have already played a key 
role in determining the factors involved in tumor initiation and 
progression(36;63;83;93;98) and are becoming increasingly important in the 
preclinical development of targeted therapies(99;100).  While much has been 
learned from genetically engineered mouse models using germline and somatically-
induced mutations, it is necessary to narrow the range of cells affected by the 
pertinent mutations.  In so doing, the progression of events from initiation to terminal 
disease can be determined in detail.  The tool we have chosen to narrow our 
population of affected cells is stereotaxic injection of a lentiviral vector expressing 
Cre-Recombinase into the cerebral cortex of the mouse.  Lentiviral vectors are 
considered an advantageous vehicle for gene delivery because of features including 
a large packaging capacity, low immune response in the host target, the ability to 
enter nondividing cells and wide host cell tropism through pseudotyping of the 
envelope glycoprotein.  They may also be engineered to be self-inactivating 
providing safety by eliminating spread from the initially infected population as well as 
limiting gene expression temporally and spatially(101;102).  This feature is 
particularly important because sustained levels of high Cre-recombinase expression 
have been shown to be toxic in brain tissue(103).  With the somatic induction of 
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genetic alterations in existing GEM models using lentiviral vectors to deliver Cre 
recombinase to the brain, we have developed a model which faithfully mimics 
disease initiation and progression as it is thought to occur in human GBM.  We have 
induced clinically pertinent alterations (Rb inactivation, Pten loss and Kras activation 
at physiologically relevant levels) in a focused population of quiescent astrocytes in 
the adult animal, while leaving the surrounding tissue unaffected.  We have found 
that mice treated in this manner develop GBM with high penetrance and a short 
latency providing an excellent model for the study of disease progression and 
molecular pathogenesis. 
 
RESULTS 
 
Development of a focal induction model for GBM 
 
 Because the RB family is frequently misregulated in human astrocytoma, the 
Van Dyke lab previously engineered TgGZT121 mice in which the function of pRb 
family members can be conditionally inactivated in astrocytes(36).  T121, an N-
terminal fragment of SV40 T-antigen, binds to and inactivates pRb and the related 
proteins, p107 and p130 without altering p53 function(104).   
 To achieve spatial and temporal control of T121 expression, we used a self-
excising lentiviral vector, introduced via stereotactic injection, to deliver Cre-
recombinase to mature astrocytes specifically in the cerebral cortex.  A single loxP 
site in the 5’ LTR of the single-stranded viral RNA is copied to the 3’ LTR upon 
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reverse transcription and integration of the provirus into the host genome(101-
103)(Fig. 2.2).  The vector contains an internal promoter from cytomegalovirus 
(CMV), used to drive transcription of immediate-early genes and thought to be 
constitutively active in a wide range of host cells.  The CMV promoter is used to 
drive expression of Cre-recombinase in infected cells.  Upon infection, the Cre-
recombinase remains active until it acts on the loxP sites in the integrated viral DNA, 
removing the genetic material necessary for its own production.  This short pulse of 
Cre is sufficient to activate conditional genetic alterations in the TgGZT121 mice 
without generating any long term cellular lethality within the sensitive neural 
tissue(103) (Fig. 2.3). 
 This same system was also used to induce other major events thought to 
occur during astrocytoma progression.  It has been previously shown that astrocyte-
specific PTEN inactivation accelerates pRb inactivation-induced astrocytoma 
development through the promotion of anti-apoptotic mechanisms, invasion and 
angiogenesis.  However PTEN inactivation, through Cre mediated excision of exons 
3 and 4, did not contribute to disease progression in these models(36;93).  These 
data suggest that additional oncogenic events are required for the transition from 
high grade astrocytoma to GBM.  It is possible that activation of receptor tyrosine 
kinase (RTK) pathways might function in this capacity (15).  In order to test this, the 
effects of activated RTK were previously modeled using a constitutively activated 
KRAS allele (K-rasG12D), which has been shown to induce astrocytoma formation 
upon somatic vector-mediated gene transfer to neural progenitors in combination 
with activated Akt(66).  In contrast to this model, physiological levels of K-rasG12D 
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were desired and obtained through use of a conditional knock-in strategy using 
KRAS+/lsl-G12D mice(83).  Upon expression of Cre-recombinase, the excision of a 
loxP-stop-loxP (lsl) cassette occurs, achieving expression of the constitutively active 
K-rasG12D. 
 Thus, in order to achieve pRbf inactivation, constitutive K-rasG12D activation 
and/or PTEN deletion specifically in a localized population of adult astrocytes, 3 
month old TgGZT121, KRAS+/lsl-G12D, PTEN+/fl and PTENfl/fl mice were injected with 
1µl of PTK-627 lentivirus (~1x106 particles) to induce the following genotypes in a 
small population of adult astrocytes: (TgG(∆Z)T121) (T), (TgG(∆Z)T121, PTEN+/-) (TP+/-) 
or (K-rasG12D , PTEN+/-) (RP+/-) or (TgG(∆Z)T121, K-rasG12D) (TR) or (TgG(∆Z)T121, K-
rasG12D and PTEN+/- or PTEN-/-) (TRP+/- and TRP-/-) (Fig. 2.1 and Table 2.1). 
 Deletion of the floxed lacZ/stop cassette and the presence of viral DNA in 
treated GZT121 animals were confirmed by PCR (Fig. 2.3E).  In the untreated 
hemisphere, recombination could not be detected and no viral DNA was found.  
Expression of T121 protein was readily detected by immunohistochemistry (IHC) as 
early as 5 days after viral injection and remained present through terminal stages 
(Fig. 2.4), but was undetectable in mock-treated littermates injected with a virus 
expressing GFP without Cre-recombinase. 
 Immunofluorescence (IF) staining was used to confirm astrocyte-specific T121 
expression (Fig. 2.3).  In GZT121 mice, T121 was observed near the injection site and 
was localized in both the nucleus and cytoplasm.  T121 also showed overlapping 
expression with GFAP protein in the cytoplasm as expected. 
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Focal Rb inactivation induces limited pathogenesis 
 One cohort of TgGZT121 mice was stereotactically injected with the PTK-627 
lentiviral vector and allowed to age for 3 weeks or 6 months to analyze both acute 
and long term effects of Rb inactivation.  At 3 weeks T121 expression was observed 
by IHC along the injection track, in the surrounding cortex and the corpus callosum.  
These data indicate that the virus is capable of infecting GFAP positive cells and 
inducing recombination within the transgene (Fig. 2.3).   
Two TgGZT121 animals were aged for a period of 6 months post-injection and 
were sacrificed without any outward signs of illness.  Following gross dissection, 
there was no discernible mass present or visible scarring from needle insertion.  
Upon histological examination, small clusters of T121 positive cells were visible at the 
injection site as well as several hundred µm distant (Fig. 2.4).  Colabeling 
experiments showed that T121 positive cells were GFAP positive as well, confirming 
that recombination in our target cells was achieved(Fig. 2.3).  Secondary structures 
of Scherer (perineuronal satellitosis) were present, but no other features of high 
grade disease were observed in the older cohort (Fig. 2.4).  While this finding differs 
from previous results demonstrating that pRB loss alone is sufficient for tumor 
initiation(36), it is not surprising considering the greatly reduced number of cells 
harboring mutations compared to previous experiments.  Focal Ras activation and 
PTEN ablation were not tested on their own, given that these alterations induced 
throughout the brain do not generate notable disease (Zhang and Van Dyke, 
unpublished). 
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pRb loss and Ras activation are necessary for tumor progression 
 As in previous work, a combinatorial approach was taken to determine the 
roles of additional mutations in disease progression in the context of focal induction.  
Three out of six mice with combined pRb inactivation and PTEN heterozygosity 
developed low grade (grade II) tumors at the site of injection over a period of 4-12 
months.  These tumors showed minimal infiltration, were non-lethal and possessed 
secondary structures of Scherer, exhibiting perineuronal satellitosis and perivascular 
satellitosis.  Interestingly, two out of three TP-/- animals developed similar features 
over a period of 10 weeks (Fig. 2.5).  Longitudinal studies were not pursued with 
these animals due to the lack of progression to high grade disease.  It was also 
found that no significant disease developed in animals with combined Kras activation 
and PTEN inactivation.  These animals were aged for a period of up to 9 months 
with no outward or histological signs of disease. 
 The combination of pRb inactivation and K-ras upregulation dramatically 
increased the severity of tumors found in treated animals.  Three out of five subjects 
developed lethal, high-grade astrocytomas over a period of 5 to 12 months.  Two of 
these three were classified as GBM (astrocytoma grade IV) with a mean survival 
time of 322 days, greatly increased mitotic index and a significantly larger and more 
invasive tumor mass possessing multiple foci of necrosis (Fig. 2.6).  These masses 
appear to have formed at the site of injection, as well as developing leptomeningeal 
spread, possibly resulting from a lack of contact inhibition on the surface of the brain.  
The GBM’s which developed were bi-hemispheric, suggesting aggressive spread of 
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tumorigenic cells.  Upon histological examination, the tumor boundary with 
surrounding parenchyma appeared to be largely discrete in H&E stained sections 
(Fig. 2.6C).  However, immunohistochemical staining for T121 revealed a very 
infiltrative tumor margin (Fig. 2.6D).   Both of the GBM’s which appeared possessed 
dilated vasculature and necrotic regions.  T121 expression was abundant within the 
tumor bulk, although it was not present within every cell (Fig 2.7), suggesting 
reversion to a more primitive phenotype which does not express GFAP or 
recruitment of surrounding cells.  It is also possible that expression of the transgenic 
and native GFAP promoters has been uncoupled, possibly receiving differing 
epigenetic signaling.  These tumors possessed immunohistochemical markers 
associated with human GBM’s.  They are largely GFAP positive, consistent with 
tumors arising from an astrocytic lineage.  They are also partially Nestin positive, 
consistent with a sub-population of precursor cells.  The tumors were largely NeuN 
negative, indicating that they lack a neural component, also consistent with human 
GBM’s (Fig. 2.7). 
Proliferation within these tumors was quantified at ~44% using Image J 
software to identify cells immunohistochemically positive for Ki-67 (a protein marker 
strictly associated with cell proliferation) in three randomly chosen fields (Fig. 2.8A).  
Virtually no proliferating cells could be located outside of the tumor region.  
Apoptosis within the tumor was also quantified at ~3%, by TUNEL assay (Terminal 
deoxyuridine triphosphate nick-end labeling) in 3 random fields (Fig. 2.8B).  Again, 
virtually no apoptotic cells were present outside of the main tumor mass. 
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High-grade tumor formation is accelerated in triple mutant animals 
 The inclusion of PTEN reduction or ablation to pRB loss and K-ras activation 
greatly reduced the latency of lethal high-grade astrocytomas (HGA).  TRP+/- 
animals survived an average of 201 days.  They also developed HGA at a higher 
frequency (10/13 subjects) than their TR counterparts (Fig. 2.10).  Five of these 
HGA’s progressed to GBM.  These animals developed tumors with a similar 
appearance to TR mice, but with much shorter latency.  TRP-/- mice developed lethal 
GBM’s even more quickly, with a mean survival time of 131 days (Table 2.2).  8/10 
developed HGA.  Six of these eight progressed to GBM (Fig. 2.10).  These tumors 
contained areas of pseudopallisading necrosis, high mitotic index, vasodilation and 
secondary structures of Scherer (Fig. 2.9).  The tumor margin is also much more 
diffuse than in TR brains, suggesting a higher capacity for invasion.  There is no 
clear boundary, and T121 positive cells can be seen diffusely infiltrating the 
surrounding tissue (Fig. 2.9B).  This result consistent with prior data demonstrating 
the role of PTEN loss in increasing migration and invasion in both in vitro and in vivo 
systems(36;93).  This diffuse invasion is consistent with human tumors, and one of 
the most confounding complications in treatment.  A steady increase in tumor 
severity is evident in the reduced survival of the mice as additional relevant 
oncogenic events are included (Fig. 2.11). 
 
DISCUSSION  
Somatic delivery is a useful tool to study clonal expansion in animal models 
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 An important feature of human tumor progression is the clonal expansion of a 
subset of tumor cells, which gain a growth advantage by acquiring additional 
genetic/epigenetic mutations(105).  In genetically engineered mouse models, 
combinations of genetic alterations are usually introduced by mating.  The somatic 
delivery approach described has several advantages over the more commonly used 
traditional knockout and xenograft models.  First, it introduces genetic mutations in 
adult mice, avoiding confounding developmental defects and circumventing possible 
lethality.  Prior models using the GFAP promoter to drive Cre expression can 
generate brain defects unrelated to tumor formation due to GFAP’s expression in a 
precursor cell type.  In the current model, Cre is briefly expressed only in infected, 
mature and quiescent cells, also avoiding any deleterious effects associated with 
long-term expression.  Secondly, it limits the area of the mutations to a carefully 
selected region, allowing the issue of tumor microenvironment to be addressed. The 
developing tumor can be studied in the context of intact brain tissue, granting more 
insight into how external factors effect progression.  Finally, somatic induction 
through viral delivery allows multiple combinations of mutations to be induced in the 
same pool of cells.  Because of the variations between transgenic lines, finding the 
same expression pattern of transgene in independent lines (even under the same 
promoter) can be challenging.  This problem is bypassed with accurate stereotaxic 
injections which allow the same portion of the brain to be targeted with excellent 
reproducibility. 
 
Multiple mutations are required for astrocytoma initiation and progression 
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 Clinical analysis of human brain tumor samples has shown that multiple 
genetic defects are present in any given case of GBM.  Recently described GEM’s 
also appear to support the hypothesis that multiple mutations are required to 
generate advanced disease.  The current model also supports this hypothesis, with 
no single mutation independently leading to astrocytoma.  It was found that 
physiological levels of KrasG12D were capable of inducing advanced tumors in the 
context of pRb inactivation with significant latency, requiring nearly a full year to 
produce GBM.  Notably, proliferation and apoptosis were elevated in these tumors.  
Ras pathway activation may also be necessary for solid tumor formation, as another 
downstream effector (VEGF) is responsible for the angiogenesis required to support 
a growing mass.  PTEN loss and pRb inactivation resulted in low-grade (Grade II) 
disease and did not progress within the time course of this study.  PTEN inactivation 
and KrasG12D produced no discernible disease after a period of 9 months.  However, 
the combination of all three events produced a localized tumor which replicated 
many of features seen in human GBM’s.  This result suggests a synergistic 
relationship between Ras pathway activation and PTEN loss, as these high-grade 
astrocytomas form much more quickly and at an increased frequency.  It remains to 
be determined if this is a direct result inhibition of apoptosis, due to deregulation of 
the PI3K signaling cascade.  This pathway is also responsible for regulating invasion 
and migration through its downstream effectors MTOR and PKCζ.  This particular 
effect of PTEN loss can clearly be seen in the diffuse tumor margin present in the 
triple mutant animals. 
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Future Directions 
 Several aspects of the effects on signaling remain unaddressed.  Levels of p-
Erk and p-Akt have not been determined within these tumor samples.  It has been 
shown that KrasG12D can also activate p-Akt, which is additionally regulated by Pten.  
It would seem that p-Akt does not reach saturation until Pten is completely ablated.  
This could be quantified through direct immunohistochemical assay for p-Akt as well 
as apoptotic index in TRP-/- brains.  A decrease in apoptosis would be expected.   
 Another interesting question that remains to be addressed is the propensity 
for other regions of the brain, aside from the cortex, to undergo tumorigenesis upon 
focal induction of oncogenic stimuli.  Cortical injections were chosen because of high 
transgene expression levels, and the mouse cortex most closely resembles the 
human cerebral hemispheres, where the majority of gliomas occur.  Future studies 
may use this focal induction model to assess other regions of the brain for 
susceptibility to tumorigenesis, as well as the testing of preclinical therapies upon 
tumor establishment.   
  
MATERIALS AND METHODS 
 
Generation of transgenic mice with conditional alleles 
GZT121 mice were produced as described(36).  Offspring were screened by 
PCR with primers:  antisense GCA TCC CAG AAG CTC CAA AG, sense GAA TCT 
TTG CAG CTA ATG GAC C.  The PCR product is bp in length.  PCR conditions are 
94o C for 2 minutes followed by 35 cycles of 94o C 20 seconds, 62o C 45 seconds, 
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72o C 2 45 seconds, and a final extension of 72o C for 2 minutes.  The recombined 
allele (∆Z) was detected using primers:  antisense TTC ATA AAG CCC TCG CAT 
CCC AGG, sense GAA TCT TTG CAG CTA ATG GAC C.  The PCR product is bp in 
length.  PCR conditions are 94o C for 2 minutes followed by 35 cycles of 94o C 30 
seconds, 64o C 30 seconds, 72o C 2 30 seconds, and a final extension of 72o C for 2 
minutes. 
Conditional Pten alleles were developed as described(36;93).  Offspring were 
screened by PCR with primers:  antisense AAA AGT TCC CCT GCT GAT GAT TTG 
T, and sense TGT TTT TGA CCA ATT AAA GTA GGC TGT G.  The PCR products 
are 435 bp (wt) and 310 bp (floxed).  PCR conditions are 94o C for 2 minutes 
followed by 35 cycles of 94o C 20 seconds, 62o C 45 seconds, 72o C 2 minutes, and 
a final extension of 72o C for 2 minutes. 
Conditional KRAS+/lslG12D mice were generated as described by the Tyler 
Jacks Lab(98).  Detection of the mutant KrasG12D allele was performed by PCR 
genotyping using primers:  antisense AGC TAG CCA CCA TGG CTT GAG TAA 
GTC TGC A, sense CCT TTA CAA GCG CAC GCA GAC TGT AGA.  The PCR 
product is ?bp in length.  PCR conditions are 94o C for 3 minutes followed by 35 
cycles of 94o C 30 seconds, 60o C 30 seconds, 72o C 2 minutes, and a final 
extension of 72o C for 5 minutes. 
Presence of the viral DNA at the injection site was also confirmed by PCR 
analysis.  Detection was performed by PCR analysis using primers: antisense 
TCTACCACACACAAGGCTACTTCCC, sense ACGAAGTTATCCTAGCCTGCAGG.  
The PCR product is 102bp in length.  PCR conditions are 94o C for 3 minutes 
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followed by 35 cycles of 94o C 30 seconds, 60o C 30 seconds, 72o C 2 minutes, and 
a final extension of 72o C for 5 minutes. 
 
Stereotactic injection 
Stereotactic injections followed standard protocols as described(77).  In brief, 
2-3 month old mice were anesthetized with Avertin and placed into a stereotaxic 
frame (KOPF).  One microliter of recombinant lentivirus PTK-627 (~109 particles per 
ml) was delivered with an infusion pump (Sage Laboratory, Orion Research) at a 
rate of 0.1 µl/min.  Coordinates used were:  (A, L, D)=0,1, and 1.2 mm from the 
Bregma suture.  These coordinates target the cerebral cortex, a known location for 
mature astrocytes where there is no evidence for neural precursors in adult animals. 
 
Tissue processing and H&E staining 
Mice were euthanized in a CO2 chamber. Brain tissue was removed and fixed 
in 10% formalin for 20 to 24hr, then stored in 70% EtOH. Fixed tissues were paraffin 
embedded and sectioned at 4-5µM. Hematoxylin and eosin staining was performed 
as previously described (39). 
 
IHC staining procedure 
Paraffin sections were deparaffinized with xylenes and rehydrated with 
ethanol/H2O, followed by a PBS wash. For antigen retrieval, sections were treated 
with citrate buffer by microwave boiling for 15 minutes, then were cooled to room 
temperature.  Slides were washed twice with double-distilled water for 5 minutes 
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then quenched in 3% H2O2 with ddH2O for 10 min. After washing, the slides were 
blocked with 5% goat serum/ PBS-T (0.1MPBS, 0.5% Tween 20) for 30min at room 
temperature. Primary antibody was diluted in 5% serum/ PBS-T and the slides were 
incubated at room temperature for 1hr (GFAP staining) or at 4°C overnight for all 
others.  Slides were washed and incubated with a 1:333 dilution of biotinylated 
secondary antibody (Vector Laboratories) in 2% serum/ PBS-T for 30 min. After 
washing, the slides were incubated with Vector’s Vectastain elite AB solution, and 
the color developed using Vector’s NovaRED substrate kit. Slides were counter 
stained using hematoxylin for 2min, or methyl green for 10 minutes, rinsed briefly in 
double-distilled water, and then rinsed in Li2CO3 for 1-3 seconds. After washing, the 
slides were dehydrated and mounted. 
Primary antibodies used were:  Dako Rabbit anti-GFAP 1:1000, Chemicon 
Mouse anti-NeuN 1:500, BD Pharmingen Mouse anti-Nestin 1:500, BD Pharmingen 
Moues anti-Ki-67 1:500, Calbiochem Mouse anti-SV40 1:200. 
 
Immunofluorescence  
    Mice were perfused with PBS at 4oC followed with 4% paraformaldehyde 
(PFA) in PBS at 4oC.  Brains were removed and post-fixed for 24 hours in 4% PFA 
at 4oC.  40 µm sections were prepared using a vibratome.  Free floating sections 
were washed 3 X 10 minutes in 0.1M PBS, blocked in 5% normal goat serum 
(Vector Laboratories) in 0.1% Triton X 100, 0.1M PBS for 30 minutes and incubated 
with the both primary antibodies diluted in 5% goat serum/PBS overnight at 4˚ C with 
shaking.  Sections were washed 3 X 10 minutes in PBS and then incubated in 
 39
secondary antibodies for 30 minutes with shaking at 4˚C.  Samples were mounted, 
coverslipped using anti-fade mounting media (Vector Laboratories Inc.) and imaged.   
The primary antibodies used were the same as listed above. 
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Figure 2.1 Relevant Genetic Constructs 
Panel A illustrates the relevant mouse genetic constructs prior to Cre expression.  In this 
configuration T121 and activated Kras are not expressed.  Wildtype PTEN is produced.  Panel 
B illustrates the genotypes after Cre-mediated recombination.  T121 and activated Kras are 
expressed.  The PTEN transcript is truncated and does not form a functional protein. 
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Table 2.1 Genotypic Abbreviations Used 
 
Abbreviation Genotype after Viral Recombination 
T TgG(∆Z)T121 
R Kras+/∆lsl-G12D 
P+/- PTEN+/- 
P+/- PTEN-/- 
TR TgG(∆Z)T121:Kras+/∆lsl-G12D 
TP+/- TgG(∆Z)T121:PTEN+/- 
TP-/- TgG(∆Z)T121:PTEN-/- 
TRP+/- TgG(∆Z)T121:Kras+/∆lsl-G12D:PTEN+/- 
TRP-/- TgG(∆Z)T121:Kras+/∆lsl-G12D:PTEN-/- 
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Figure 2.2 PTK-627 lentiviral structure 
The top portion of the panel shows the plasmid used as part of the 3 plasmid transient 
transfection system in the host packaging cell line.  The cell line produces replication 
incompetent VSVG pseudotyped virus that may be concentrated to very high titers.  The 
middle portion illustrates the integrated provirus in the host genome following reverse 
transcription and duplication of the LTR.  The bottom portion indicates the remaining 
exogenous sequences in infected cells following a brief period of Cre expression. 
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Figure 2.3  T121 Expression is Restricted to Astrocytes 
GFAP intermediate filament expression in the adult cortex is a marker of adult astrocytic 
phenotype (A).  T121 protein expression is specifically localized only in cells which also 
express GFAP (C), indicating appropriate regulation of the transgene in our target cells 19 
days post-injection.  T121 expression was not found in any location in the brain other than 
the injection site.  Panel E demonstrates PCR evidence of viral DNA at the injection site.  
Upper arrow indicates 102 bp viral recombination product.  Lower arrow indicates primer 
dimer band.  Lane 1 is DNA from an induced GZT121 animal.  Lane 2 is DNA isolated from 
a TRP tumor.  Lane 3 is DNA isolated from the same animal, but derived from the untreated 
hemisphere.  Scale bar = 20 µm.   
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Figure 2.4 Stable Long Term T121 Expression 
T121 staining (brown) is evident 6 months post-injection at the treatment site.  Notably, there 
are several clusters of positive cells up to 2mm away from the site of injection.  Panel A: 
100x magnification T121 negative control B: 400x magnification T121 Negative control C: 
100x magnification T121 D: 400x magnification T121. 
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Figure 2.5  RB loss and PTEN Reduction Results in Focal Hyperplasia 
Panel A is a low power image (100x magnification) demonstrating localized cell clusters, 
indicated by arrows, appearing 6 months post-injection in TP+/- animals.  Panel B is a high 
power image (400x magnification) showing specific secondary structures of astrocytoma, 
perivascular and perineuronal satellitosis (arrows). 
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Figure 2.6  Features of TR GBM’s 
Panel A is a 400x magnification showing abnormal vasculature, including vasodilation.  
Several mitotic cells are visible.  Panel B is a 100x magnification showing a large area of 
necrosis next to several foci of incipient necrosis.  Panel C is a 100x magnification 
illustrating the apparently sharp tumor margin in contact with normal brain parenchyma.  
Panel D is a 400x magnification demonstrating invading tumor cells at the margin of the 
lesion.  T121 is pictured in green, GFAP is pictured in red and DAPI is pictured in blue. 
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Figure 2.7 Histological Characterization of TR GBM 
 
TR GBM’s are immunohistochemically positive for T121 as well as other markers associated 
with human GBM, including Nestin and GFAP.  Panel A: 100x T121 negative control B: 100x 
T121 C: 400x T121 D: 100x GFAP negative control E: 100x GFAP F: 400x GFAP G: 100x 
Nestin negative control H: 10x Nestin I: 400x Nestin. 
 
 
 48
 
 
 
 
Figure 2.8  Proliferation and Apoptosis in TR animals 
Proliferation was evaluated by Ki-67 immunoreactivity within the tumor.  >44% of cells 
were positive for this marker (A and C).  In contrast, normal adult mouse brain has virtually 
no proliferating cells outside of specific compartments.  Apoptosis was also elevated within 
the tumors as evaluated by TUNEL assay (B and D).   
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Figure 2.9 Features of GBM observed in terminal stage TRP Animals 
Panels A and C show regions of necrosis within the tumor mass.  Panel B shows the diffusely 
infiltrating nature of these tumors, T121 positive cells in brown can be seen outside the main 
tumor mass.  Panel D shows mitosis and perivascular satellitosis occurring outside the main 
tumor mass. 
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Figure 2.10  Tumor Incidence 
Tumor frequency in all genotypes.  Red bars denote percentage of astrocytomas in all treated 
animals.  Green bars denote percentage of High-grade astrocytomas out of all astrocytomas.  
Blue bars denote percentage of GBM’s out of all High-grade astrocytomas. 
 51
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Figure 2.11 Tumor Free Survival 
Kaplan-Meier survival curves of all relevant GEM.  Survival steadily decreases with the 
addition of oncogenic events.  Notably T and TP animals did not develop terminal disease 
over the course of the study.  TR animals required nearly a year to develop GBM.  The 
addition of PTEN heterozygosity reduced latency to 6.5 months.  PTEN knockout further 
decreased survival to 4.5 months. 
 
 
 
Table 2.2.  Somatic induction of astrocytomas in conditional GEM 
 
Genotype 
Mice (N) 
Incidence 
(%) 
HGA 
(%) 
GBM 
(%) 
Overall 
Survival 
With HGA  
(mean ± 
SEM) 
Injected Developed Astrocytomas 
T 6 0 0 0 0 N/A 
TP+/- 3 2 67 0 0 N/A 
TP-/- 6 3 50 0 0 N/A 
TR 5 2 40 2 (100) 2 (100) 322 ± NA 
TRP+/- 13 10 77 5 (50) 3 (60) 201 ± 31 
TRP-/- 11 7 64 5 (71) 3 (60) 131 ± 25 
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